BRISTOL MYERS SQUIBB

The Global Monoclonal Antibodies Market is projected to grow from USD 279.8 billion in 2024 to USD 804.7 billion by 2033, at a CAGR of 12.5%. North America is expected to dominate with a 47.5% share in 2024, driven by strong healthcare infrastructure and high R&D investments. Oncology is projected to lead the application segment with a 46.2% share. Major companies include Roche, Novartis, Johnson & Johnson, Pfizer, and Merck.

Nivolumab plus gemcitabine/cisplatin chemotherapy significantly improved response rates, overall survival, and progression-free survival in patients with lymph node–only metastatic urothelial carcinoma, according to a post hoc analysis of the CheckMate 901 trial presented at the 2024 ASCO Annual Meeting.

Global Monoclonal Antibodies Market to reach USD 804.7 billion by 2033, growing at a CAGR of 12.5% from USD 279.8 billion in 2024. Dominated by North America, human-derived antibodies, and oncology applications, with key players including Roche, Novartis, and Johnson & Johnson.

Adding novel agents to perioperative durvalumab for NSCLC led to higher pCR and mPR rates compared to historical rates with durvalumab and chemotherapy. The highest response rates occurred with the addition of Dato-DXd (pCR 34.1%, mPR 65.9%). All combinations demonstrated manageable safety profiles and surgical rates comparable to approved regimens.

Candid Therapeutics, a biotech startup, launched with $370 million to develop T-cell engager drugs for inflammatory diseases, acquiring rights to two cancer drug prospects from Vignette Bio and TRC 2004. CEO Ken Song believes T-cell engagers are a better solution for autoimmune diseases than cell therapy due to lower production costs and easier administration. The company plans to start clinical trials for autoimmune conditions next year.

Latigo Biotherapeutics appoints Tim Lugo as CFO and adds Beth Seidenberg and Jim Tananbaum to its board, aiming to advance non-opioid pain medicine development.

Latigo Biotherapeutics appoints Tim Lugo as CFO and Beth Seidenberg, M.D., and Jim Tananbaum, M.D., to its board to advance non-opioid pain medicine development.

Ultimovacs ASA presented updated data from the UV1 Phase II NIPU trial at the 2024 ESMO Congress, showing a meaningful benefit on secondary endpoints like objective response rate (ORR) and overall survival (OS) in patients with inoperable malignant pleural mesothelioma treated with UV1 plus ipilimumab and nivolumab.

ESMO 2024 in Barcelona will feature discussions on cancer therapeutics, including anticipated presentations on bispecific antibodies and anti-TIGIT therapies. Other topics include radioligand therapies and synthetic lethality assets. Experts are optimistic about the potential of these therapeutic classes, despite past challenges.

Ultimovacs ASA presented updated data from the UV1 Phase II NIPU trial at the 2024 ESMO Congress, showing increased clinical benefit for the epithelioid subgroup, with a median PFS improvement of 5.5 months for UV1 combined with ipilimumab and nivolumab versus 2.9 months for immunotherapy alone. The trial did not meet the primary endpoint of improved PFS but demonstrated a doubling of ORR and a 27% reduction in death risk.